Archive for July 15th, 2012

ACAD Phase 3 data expected 4Q. SUPN PDUFA date confirmed. THRX file NDA and MAA for COPD

Jul 15, 2012 No Comments by

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) said in a SEC filing that it expects to complete enrolment in its Phase 3 efficacy, tolerability and safety trial with pimavanserin for Parkinson’s disease psychosis, during August 2012. Data is expected later in 4Q 2012. Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) confirmed the PDUFA date for SPN-804 (extended-release oxcarbazepine) for epilepsy, is October […]

Daily News Read more